University of Florida origins. Global potential.

Originally housed at the University of Florida's award-winning Sid Martin Biotech Incubator (2012-2015), Prometheon Pharma's patented Topicon™ transdermal technology is poised to make a global impact with convenient, affordable, biodegradable extended-wear drug patches that require little refrigeration. These patches are simple and inexpensive enough to help address global pandemics and provide better delivery alternatives for orphan disease treatments alike. On the foundation of this platform technology, Prometheon seeks to build a socially responsible and globally oriented pharmaceutical and biotechnology company, comprised of ethically conscious individuals of diverse talents, creating innovative solutions for the world's greatest threats to health and humanity. 


Stephen Hsu, MD, PhD, Founder, CEO/CSO, Board Member

Stephen Hsu is a Harvard-trained, internationally acclaimed physician-scientist with a passion for patient engagement and global health solutions through the application of clinical translational research. Steve has several patents to his name with previous products commercialized from nearly two decades of characterizing the TRIP-Br family of proteins he discovered during his clinical fellowship at the Massachusetts General Hospital. They function as regulators of the cell cycle, turning genes on and off, as well as playing the role of a master regulator of the balance between fat utilization vs. storage in the case of TRIP-Br1, which is now a therapeutic target for developing a novel class of anti-obesity drugs. Steve is formerly the first occupant of the R. Glenn Davis Endowed Chair in Clinical and Translational Medicine and Director of the MD-PhD program at the University of Florida.

In the fall of 2012, Steve left academia to focus his efforts full-time on commercializing his invention of Topicon™, specifically developed to enable the passive transdermal delivery of peptide drugs such as insulin. His list of candidate large and small molecule drugs that would be ideally delivered in the embodiment of  extended-wear TruePatch™ products grows daily. Steve is also spearheading the development of a novel class of anti-obesity drugs based on his research group's January 2013 co-publication in Nature Medicine with collaborators at the Joslin Diabetes Center (Harvard Medical School) to address the global pandemic of obesity and type 2 diabetes.


Hua Yao, PhD, Director of Research and Development

Hua Yao brings an extensive background in medicinal chemistry, pharmaceutics, and transdermal drug formulation. She oversees the conception, execution, and technical evaluation of studies for our in-house new product development program as well as for our industry and academic partners. Hua received her Ph.D. in medicinal chemistry from the University of Florida in 2007 with a focus on anti-cancer and orphan drug development and delivery methods. Subsequently, she completed two NIH-funded postdoctoral fellowships to expand her research areas in histopathology of degenerative CNS diseases and pharmacodynamics of anti-obesity peptide drugs


Helen Goh, BA, Director of Marketing and Communications

Helen Goh brings 18 years of advertising account management and global strategic development experience from agencies including Euro RSCG (Havas), DDB Needham (Omicom), and Dentsu Young and Rubicam (WPP). She served as Group Account Director for major accounts such as Intel, Citibank and Chase. In other marketing roles, Helen has worked for Turner Broadcasting Corp , Chinadotcom Corp,  and McDonald’s Corp’s Pret A Manger

Helen received her BA in sociology from the National University of Singapore and is currently the Director of Communications and Marketing (College of Engineering) at the University of Florida. Helen Goh and Dr. Stephen Hsu are married.



Roger S. Mazze, PhD, Chairman of the Board

Roger Mazze is the Director of the AGP Clinical Academy (Bristol, UK) and currently Visiting Professor at Nanjing Medical University (China). Until recently, he was Senior Vice President of the Park Nicollet Institute and Chief Academic Officer of the International Diabetes Center (IDC), and is widely acknowledged as one of the most important innovators in the field of diabetology, having made numerous major contributions in the improvement of diabetes care and patient outcomes worldwide. Most recently, he led the US faculty teaching and research team of the China Initiative for Diabetes Excellence (CIDE) jointly developed with the Chinese Diabetes Society, and conducted under the auspices of the Chinese Ministry of Health. Credited with the development of memory-based reflectance meters for glucose self-monitoring, he moved to the IDC in 1988 where he developed and led the first academic laboratory devoted to advanced computer technologies in diabetes care. His work with ambulatory glucose profile (AGP) and Staged Diabetes Management (SDM) is recognized and utilized all over the world. Roger serves as Prometheon’s scientific affairs liaison.

Frank M. Silver, PhD, Vice-Chairman of the Board

Frank Silver is a material science expert currently collaborating with Dr. Hsu to create a completely heat-resistant transdermal patch (HeatWave™) for the delivery of perishable peptide and protein drugs in equatorial regions of the world. Frank is a highly accomplished former industry executive and a highly successful private entrepreneur who brings with him a wealth of experience in leadership and business spanning over four decades. Frank has deep experience in commercializing technology with companies, academia, and governments, based on his career at Monsanto and thereafter his consulting company. Frank earned his BSc in Chemistry from the University of North Carolina-Chapel Hill, followed by pre-doctoral research on conversion of squalene to cholesterol for which he was conferred his PhD in Organic Chemistry from the University of Wisconsin-Madison in 1970. Frank serves as Prometheon’s industry and business development liaison.


Richard Miles, BA, MS, Board Member

Richard Miles is co-founder and Vice President of the Cade Museum for Creativity and Invention in Gainesville, Florida. The mission of the Cade Museum, which will open in late 2015, is to inspire creative thinking, future inventors, and early entrepreneurs. He received a BA in Russian Studies from the University of Washington in 1987, and an MSc in Foreign Service from Georgetown University in 1993.  He is fluent in Spanish and German. Prior to joining the Cade Museum, Richard was a career Foreign Service Officer with the US Department of State. From 2006-2008, Richard worked at the White House on the National Security Council (NSC) as Director for North America and as the Executive Assistant Director to the Deputy National Security Advisor. From 2008 to 2009, he served as a civilian adviser on a Provincial Reconstruction Team in Karbala, Iraq. Prior to the NSC, he had a variety of diplomatic assignments abroad, including Argentina, Germany, and Barbados. Before entering the Foreign Service, Richard was an intelligence officer in the US Army, stationed with the Second Armored Cavalry Regiment (ACR) in Nuremberg, Germany from 1988 to 1991 and participated in Operations Desert Shield and Desert Storm in 1991.  Richard serves as Prometheon’s liaison to advocacy groups, lobbyists and government agencies, domestic and foreign.